Innovent Biologics Secures License for Large-Scale Biologics Production in China
Innovent Biologics, a Chinese biopharmaceutical company, has received a license from China's National Medical Products Administration (NMPA) to operate a large-scale biologics production plant in Hangzhou. This facility, featuring four 20,000-liter bioreactors, is the first of its kind in China to be licensed for drug product manufacturing. The license was granted following an assessment of the plant's compliance with good manufacturing practices (GMPs), confirming that its quality systems and technologies meet the required standards. Innovent's contract development and manufacturing organization, Altruist Biologics, plans to expand the facility's capacity to 172,000 liters, significantly increasing its manufacturing capabilities. This expansion includes the development of modalities such as antibodies, fusion proteins, and antibody-drug conjugates (ADCs). The Hangzhou site is part of Innovent's broader strategy to enhance its manufacturing footprint, which also includes a 60,000-liter plant in Suzhou. 
